Logo

Boehringer Ingelheim and Eli Lilly Present Results of Jardiance (empagliflozin) in P-III EMPEROR-Preserved Trial for the Treatment of HFpEF at ESC 2021

Share this

Boehringer Ingelheim and Eli Lilly Present Results of Jardiance (empagliflozin) in P-III EMPEROR-Preserved Trial for the Treatment of HFpEF at ESC 2021

Shots:

  • The P-III EMPEROR-Preserved trial evaluates the safety & efficacy of empagliflozin (10mg- qd) vs PBO in 5988 patients with chronic HFpEF
  • The results demonstrated a 21% reduction in risk for composite 1EPs of CV death or hospitalization for HF. The 2EPs showed a 27% reduction in risk of first & recurrent hospitalizations for HF & slowed kidney function decline- safety data were consistent with previous findings with well-established safety profile of empagliflozin- results are published in the NEJM
  • The companies plan for regulatory submissions globally in 2021. If approved- empagliflozin will be the 1st therapy across the HF spectrum

  Ref: Businesswire | Image: Boehringer Ingelheim 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions